Journal of Health Sciences and Clinical Technology

OCT 29, 2026 · JOURNAL ARTICLE

Mechanisms, Limitations, and Prospects of PARP Inhibitor Talazoparib and MTH1 Inhibitor Karonudib for Malignant Tumor Therapy

Journal of Health Sciences and Clinical Technology

Cancer cells rely heavily on DNA damage repair mechanisms for survival, making the targeting of the DNA damage response (DDR) pathway an important direction for cancer treatment. N

OCT 29, 2026 · JOURNAL ARTICLE

STF31 Targeting GLUT1 in VHLDeficient Clear Cell Renal Cell Carcinoma

Journal of Health Sciences and Clinical Technology

VHL gene is a typical gene that is frequently mutated in clear cell renal cell carcinoma (ccRCC). It can promote the expression of glucose transporter 1 (GLUT1) and the Warburg eff

OCT 29, 2026 · JOURNAL ARTICLE

Mechanism of MYC Oncogene in Tumor Cell Proliferation

Journal of Health Sciences and Clinical Technology

MYC proto-oncogene (MYC) is a well-known oncogene that can act as a transcription factor. Its abnormal activation can be observed in nearly all types of human malignant tumors. Ins

OCT 29, 2026 · JOURNAL ARTICLE

Mechanisms of SPP1+/TREM2+ Tumor- Associated Macrophag+s in Immunotherapy Resistance and Combined Targeted Therapy Strategies

Journal of Health Sciences and Clinical Technology

Immunotherapy resistance in solid tumors is closely related to multi-level immunosuppression in the tumor microenvironment (TME), with tumor-associated macrophages (TAMs) playing a